In vitro and in vivo studies of homocysteine in equine tissues: Implications for the pathophysiology of laminitis

Equine Veterinary Journal

Volumn 36, Issue 3, 2004, Pages 279-284

  Berhane, Y ^a   Bailey, S R ^a   Harris, P A ^b   Griffiths, M J ^c   Elliott, J ^a  

^a ROYAL VETERINARY COLLEGE   (United Kingdom)

^b WALTHAM CENTRE FOR PET NUTRITION   (United Kingdom)

^c UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Endothelium; Homocysteine; Horse; Plasma

Indexed keywords

HOMOCYSTEINE; NITRIC OXIDE;

AMINO ACID BLOOD LEVEL; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CELL FUNCTION; CONTROLLED STUDY; ENDOTHELIUM CELL; HORSE DISEASE; IN VITRO STUDY; IN VIVO STUDY; LAMINITIS; NONHUMAN; PATHOPHYSIOLOGY; SYSTEMIC DISEASE; TISSUE LEVEL; VASCULAR ENDOTHELIUM;

ANIMALIA; EQUIDAE; EQUUS CABALLUS;

EID: 2542634929     PISSN: 04251644     EISSN: None     Source Type: Journal    
DOI: 10.2746/0425164044877161     Document Type: Article

References (33)

1. al-Awami, M., Schillinger, M., Maca, T., Gschwandtner, M., Bieglmayer, C., Wagner, O. and Minar, E. (2002) Homocysteine levels in patients with Raynaud's phenomenon. Vasa. 31, 87-90.
2. Bailey, S.R., Wheeler-Jones, C. and Elliott, J. (2003) Uptake of 5-hydroxytryptamine by equine digital vein endothelial cells: inhibition by amines found in the equine caecum. Equine vet. J. 35, 164-169.
3. Bates, N.J., Baker, M.T. and Guerra, R.J. (1991) Nitric oxide generation from nitroprusside by vascular tissue: evidence that reduction of the nitroprusside anion and cyanide loss are required. Biochem. Pharmacol. 42, S157-S165.
4. Bellamy, M.F., McDowell, I.F.W., Ramsey, M.W., Brownlee, M., Bones, C., Newcombe, R.G. and Lewis, M.J. (1998) Hyperhomocysteinemia after an oral methionine load acutely Impairs endothelial function in healthy adults. Circulation 98, 1848-1852.
5. Berhane, Y., Bailey, S.R. and Elliott, J. (2003) Characterisation of endothelium-dependent vasodilatory responses in the equine isolated perfused digital vascular bed. Br. J. Pharmacol. 138, 146.
6. Boushey, C.J., Beresford, S.A., Omenn, G.S. and Motulsky, A.G. (1995) A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. J. Am. med. Ass. 274, 1049-1057.
7. Bryant, C.E. and Elliott, J. (1994) Nitric oxide: friend or foe? Equine vet. Educ. 6, 59-64.
8. Chow, K., Cheung, F., Lao, T.T. and O, K. (1999) Effect of homocysteine on the production of nitric oxide in endothelial cells. Clin. expt. Pharmacol. Physiol. 26, 817-818.
9. Cogswell, A.M., Johnson, P.J. and Adams, H.R. (1995) Evidence for endothelium-derived relaxing factor/nitric oxide in equine digital arteries. Am. J. vet. Res. 56, 1637-1641.
10. Dennis, V.W. and Robinson, K. (1996) Homocysteinemia and vascular disease in end-stage renal disease. Kidney Int. 57, 11-17.
11. Elliott, J., Bryant, C.E. and Soydan, J. (1994) The role of nitric oxide in the responses of equine digital veins to vasodilator and vasoconstrictor agents. Equine vet. J. 26, 378-384.
12. Elmes, P.J. and Eyre, P. (1977) Vascular reactivity of the bovine foot to neurohormones, antigens and chemical mediators of anaphlaxis. Am. J. vet. Res. 38, 107-112.
13. Freedman, R.R., Girgis, R. and Mayes, M.D. (2001) Abnormal responses to endothelial agonists in Raynaud's phenomenon and scleroderma. J. Rheumatol. 28, 119-121.
14. Hinckley, K.A., Fearn, S., Howard, B.R. and Henderson, I.W. (1996) Glyceryl trinitrate enhances nitric oxide mediated perfusion within the equine hoof. J. Endocrinol. 151, R1-8.
15. Hood, D.M., Amoss, M.S. and Grosenbaugh, D.A. (1990) Equine laminitis: a potential model of Raynaud's phenomenon. Angiol. 41, 270-277.
16. Hood, D.M., Grosenbaugh, D.A., Mostafa, M.B., Morgan, S.J. and Thomas, B.C. (1993) The role of vascular mechanisms in the development of acute equine laminitis. J. vet. Int. Med./Am. Coll. vet. int. Med. 7, 228-234.
17. Jin, L., Abou-Mohamed, G., Caldwell, R.B. and Caldwell, R.W. (2001) Endothelial cell dysfunction in a model of oxidative stress. Med. Sci. Monit. 7, 585-591.
18. Kang, S., Zhou, J., Wong, P.W., Kowalisyn, J. and Strokosch, G. (1988) Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am. J. Hum. Genet. 43, 414-421.
19. Lang, D., Kredan, M.B., Moat, S.J., Hussain, S.A., Powell, C.A., Bellamy, M.F., Powers, H.J. and Lewis, M.J. (2000) Homocysteine-induced inhibition of endothelium-dependent relaxation in rabbit aorta: role for superoxide anions. Arterioscler. Thromb. vasc. Biol. 20, 422-427.
20. Levy, Y., George, J., Langevitz, P., Harats, D., Doolman, R., Sela, B.A. and Shoenfeld, Y. (1999) Elevated homocysteine levels in patients with Raynaud's syndrome. J. Rheumatol. 26, 2383-2385.
21. Marasini, B., Casari, S., Bestetti, A., Maioli, C., Cugno, M., Zeni, S., Turri, O., Guagnellini, E. and Biondi, M.L. (2000) Homocysteine concentration in primary and systemic sclerosis associated Raynaud's phenomenon. J. Rheumatol. 27, 2621-2623.
22. Martin, S.C., Tsakas-Ampatzis, I., Bartlett, W.A. and Jones, A.F. (1999) Measurement of plasma total homocysteine by HPLC with coulometric detection. Clin. Chem. 45, 150-152.
23. McDowell, I.F.W. and Lang, D. (2000) Homocysteine and endothelial dysfunction: a link with cardiovascular disease. J. Nutr. 130, 369-000.
24. Mombouli, J.V. and Vanhoutte, P.M. (1999) Endothelial dysfunction: from physiology to therapy. J. mol. cell. Cardiol. 31, 61-74.
25. Perry, I.J., Refsum, H., Morris, R.W., Ebrahim, S.B., Ueland, P.M. and Shaper, A.G. (1995) Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 346, 1395-1398.
26. Schini, V.B., Boulanger, C., Regoli, D. and Vanhoutte, P.M. (1990) Bradykinin stimulates the production of cyclic GMP via activation of B2 kinin receptors in cultured porcine aortic endothelial cells. J. Pharmacol. exp. Therap. 252, 581-585.
27. Selhub, J. and Miller, J.W. (1992) The pathogenesis of homocysteinemia: interruption of the coordinate regulation by S-adenosylmethionine of the remethylation and transsulfuration of homocysteine. Am. J. clin. Nutr. 51, 131-138.
28. Stuhlinger, M.C., Tsao, P.S., Her, J.H., Kimoto, M., Balint, R.F. and Cooke J.P. (2001) Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation 104, 2569-2575.
29. Sunder-Plassmann, G. and Fodinger, M. (2003) Genetic determinants of the homocysteine level. Kidney Int., Suppl. 84, S141-144.
30. van der Griend, R., Biesma, D.H. and Banga, J.D. (2000a) Hyperhomocysteinaemia as a cardiovascular risk factor: an update. Netherlands J. Med. 56, 119-130.
31. van der Griend, R., Biesma, D.H. and Banga, J.-D. (2000b) Hyperhomocysteinaemia as a cardiovascular risk factor: an update. Netherlands J. Med. 56, 119-130.
32. Welch, G.N. and Loscalzo, J. (1998) Homocysteine and atherothrombosis. N. Engl. J. Med. 338, 1042-1050.
33. Zhang, X., Li, H., Jin, H., Brodsky, S. and Goligorsky, M.S. (2000) Effects of homocysteine on endothelial nitric oxide production. Am. J. Physiol. Renal Physiol. 279, F671-678.